Produktname:3-Bromo-5-(chloromethyl)pyridine
IUPAC Name:3-bromo-5-(chloromethyl)pyridine
- CAS：120277-69-2
- Molekulare Formel：C6H5BrClN
- Reinheit：95%
- Katalognummer：CM175066
- Molekulargewicht：206.47
Nur für den Einsatz in Forschung und Entwicklung..
Produkt-Details
- CAS-Nr.:120277-69-2
- Molekulare Formel:C6H5BrClN
- Schmelzpunkt:-
- SMILES-Code:ClCC1=CN=CC(Br)=C1
- Dichte:
- Katalognummer:CM175066
- Molekulargewicht:206.47
- Siedepunkt:
- Mdl-Nr.:MFCD10697600
- Lagerung:Store at 2-8°C.
Category Infos
- Pyridines
- Pyridine is a six-membered heterocyclic compound containing one nitrogen heteroatom. Pyridine and piperidine are the most frequently occurring heterocyclic building blocks in drug molecules. According to incomplete statistics, there are currently more than 180 drugs containing pyridine or piperidine structure that have been marketed, nearly 1/5 of the drugs approved for marketing in recent years contain these two structures.
- Pyridine | C5H5N | Pyridine Supplier/Distributor/Manufacturer - Chemenu
- Pyridine,Pyridine Wholesale,Pyridine for Sale,Pyridine Supplier,Pyridine Distributor,Pyridine Manufacturer
- Pyridine is a basic heterocyclic organic compound with the chemical formula C5H5N. It is structurally related to benzene, with one methine group (=CH−) replaced by a nitrogen atom. It is a highly flammable, weakly alkaline, water-miscible liquid with a distinctive, unpleasant fish-like smell.
Column Infos
- ALX-001
- Allyx Therapeutics has announced that the first patient has been dosed with its lead compound, ALX-001, in a new clinical study assessing safety, pharmacokinetics and potential therapeutic response in patients with Parkinson’s disease. ALX-001 (previously BMS-984923) is a silent allosteric modulator of mGluR5, and is a first-in-class compound that selectively blocks the pathogenic activation of the receptor while preserving the normal physiological glutamate signaling that is required for cognition. As such, ALX-001 has a wide therapeutic window that can saturate receptors while avoiding on-target toxicity observed with negative allosteric modulators. mGluR5 has been shown to be essential for mediating synaptic dysfunction and loss caused by multiple misfolded extracellular protein species, and as such, presents a novel approach for treating Alzheimer’s and Parkinson’s disease.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.
Suche 
+86 21 5895 0110 
